You are here

P&T News

November 22

New combo is a maintenance treatment for virologically suppressed HIV-1

November 21

Researchers find opioid-agonist treatment saves lives and money compared with detox
Tirasemtiv did not differentiate itself from placebo in phase 3 study
Instead of targeting CD19 on the surface of cancer cells, new approach targets CD22
Four in 10 U.S. cases and deaths are linked to risk factors we can change
Approach could help slow growth of antibiotic-resistant bacteria

November 20

Five sepsis deaths had been reported in late-phase trials
Patients can avoid long drives to distant specialists
Needle length and dose target patients weighing 16.5 to 33 pounds

November 17

In study, progression-free survival was superior to Rituxan-based therapy

November 16

This is the first new medicine for this population in two decades
First agency-approved treatment for pediatric and adult patients with MPS VII
FDA clears NSS-2 Bridge in an effort to reduce symptoms
FDA establishes a pathway to speed approval for similar tests
Acorda Therapeutics hits pause on trial enrollment for tozadenant
New indication marks first adjuvant treatment after nephrectomy

November 15

First respiratory biologic with an eight-week maintenance dosing schedule

November 14

Under guidelines, nearly half of U.S. population will be diagnosed with hypertension
NK1 receptor antagonist helps with moderately and highly emetogenic chemotherapies

Pages